Briacell Therapeutics
BCTX
19 hedge funds and large institutions have $4.77M invested in Briacell Therapeutics in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 14 closing their positions.
14% less funds holding
Funds holding: 22 → 19 (-3)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
22.67% less ownership
Funds ownership: 26.53% → 3.86% (-23%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
76% less capital invested
Capital invested by funds: $20.3M → $4.77M (-$15.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Voloridge Investment Management
Jupiter,
Florida
|
+$962K |
| 2 |
Two Sigma Investments
New York
|
+$381K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$247K |
| 4 |
Jane Street
New York
|
+$216K |
| 5 |
VF
Virtu Financial
New York
|
+$202K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$4.27M |
| 2 |
AC
Armistice Capital
New York
|
-$3.04M |
| 3 |
KC
Kepos Capital
New York
|
-$2.67M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.13M |
| 5 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$2.13M |
BCTX Hedge Fund Activity: Q3 2021 in Review
19 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q3 2021, worth a combined $4.77M — down 76% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of BCTX and 11 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Voloridge Investment Management, opening a new position worth an estimated $962K. The largest seller was Altium Capital Management, exiting entirely with an estimated $4.27M sold.
- 19 institutional investors held Briacell Therapeutics (BCTX) as of Q3 2021, down from 22 in Q2 2021.
- Funds reported $4.77M of Briacell Therapeutics stock for Q3 2021, down 76% quarter-over-quarter.
- 11 funds opened new Briacell Therapeutics positions in Q3 2021 and 14 closed out, a net change of -3 holders.
- The largest Briacell Therapeutics buyer in Q3 2021 was Voloridge Investment Management, an estimated $962K added.
- The largest Briacell Therapeutics seller in Q3 2021 was Altium Capital Management, an estimated $4.27M sold.
Based on aggregated 13F filings for Q3 2021.